These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Erythropoiesis-stimulating protein delivery in providing erythropoiesis and neuroprotection. Chang ZY; Chiang CH; Lu DW; Yeh MK Expert Opin Drug Deliv; 2008 Dec; 5(12):1313-21. PubMed ID: 19040394 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological Neuroprotection of the Preterm Brain: Current Evidence and Perspectives. Siahanidou T; Spiliopoulou C Am J Perinatol; 2022 Apr; 39(5):479-491. PubMed ID: 32961562 [TBL] [Abstract][Full Text] [Related]
10. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review. Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152 [TBL] [Abstract][Full Text] [Related]
11. Neuroprotection with erythropoietin in preterm and/or low birth weight infants. Zhang J; Wang Q; Xiang H; Xin Y; Chang M; Lu H J Clin Neurosci; 2014 Aug; 21(8):1283-7. PubMed ID: 24650681 [TBL] [Abstract][Full Text] [Related]
12. The long-term effect of erythropoiesis stimulating agents given to preterm infants: a proton magnetic resonance spectroscopy study on neurometabolites in early childhood. Gasparovic C; Caprihan A; Yeo RA; Phillips J; Lowe JR; Campbell R; Ohls RK Pediatr Radiol; 2018 Mar; 48(3):374-382. PubMed ID: 29335880 [TBL] [Abstract][Full Text] [Related]
13. The comparative effects of recombinant human erythropoietin and darbepoetin-alpha on cerebral vasospasm following experimental subarachnoid hemorrhage in the rabbit. Kertmen H; Gürer B; Yilmaz ER; Arikok AT; Kanat MA; Ergüder BI; Sekerci Z Acta Neurochir (Wien); 2014 May; 156(5):951-62. PubMed ID: 24497025 [TBL] [Abstract][Full Text] [Related]
14. The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients. Park LC; Song YJ; Kim DJ; Kim MJ; Jo JC; Lee WS; Shin HJ; Oh SY; Do YR; Jeong JY; Lee HS; Int J Cancer; 2019 Nov; 145(9):2459-2467. PubMed ID: 30973963 [TBL] [Abstract][Full Text] [Related]
15. Urinary erythropoietin concentrations after early short-term infusion of high-dose recombinant epo for neuroprotection in preterm neonates. Dame C; Langer J; Koller BM; Fauchère JC; Bucher HU Neonatology; 2012; 102(3):172-7. PubMed ID: 22776958 [TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effect of erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage. Grasso G; Graziano F; Sfacteria A; Carletti F; Meli F; Maugeri R; Passalacqua M; Certo F; Fazio M; Buemi M; Iacopino DG Neurosurgery; 2009 Oct; 65(4):763-9; discussion 769-70. PubMed ID: 19834382 [TBL] [Abstract][Full Text] [Related]
18. Future alternative therapies in the pipeline for mild neonatal encephalopathy: Review of evidence of neuroprotection with erythropoiesis stimulating agents. DuPont T; Chalak L Early Hum Dev; 2018 May; 120():95-98. PubMed ID: 29471979 [No Abstract] [Full Text] [Related]
19. Erythropoietin and erythropoiesis stimulating agents. Debeljak N; Sytkowski AJ Drug Test Anal; 2012 Nov; 4(11):805-12. PubMed ID: 22508651 [TBL] [Abstract][Full Text] [Related]
20. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model. Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]